Medivation successfully tested a new antitumor drug

news

A new PARP inhibitor developed by Medivation successfully clinical trials of Phase II in the treatment of advanced breast cancer among patients with a mutation of BRCA1 / 2 genes previously chemotherapy with platinum, informs Reuters.
According to published data, the use of the experimental drug talazoparib (talazoparib) contributed to tumor reduction in 21 and 37% of patients with progressive oncopathology after one and at least three courses of chemotherapy with platinum drugs, respectively.The average survival rate without disease progression was 4 and 5.6 months in these groups.
Currently, patients are selected for participation in phase III clinical trials, whose task will be to evaluate the effectiveness of thalazoparib in the treatment of ovarian, stomach, NSCLC in combination with other drugs.
In August last year, Pfizer bought Medivation for $ 14 billion. In the portfolio Medivation is an antitumor drug enzalutamide (enzalutamide), approved for the therapy of metastatic prostate cancer. Sales of this drug, known on the market as Kstandi, last year amounted to about $ 2 billion, and according to experts' forecasts, drug sales in the near future can grow by half.

A source:

Remedium